Vir Biotechnology (NASDAQ:VIR) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?

Vir Biotechnology, Inc. (NASDAQ:VIR) shares passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $11.03 and traded as high as $12.45. Vir Biotechnology shares last traded at $12.21, with a volume of 1,887,037 shares trading hands.

Key Stories Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Analyst sentiment improved: Needham raised its price target to $20 from $18 and maintained a Buy rating. Zacks Research also upgraded VIR from Strong Sell to Hold, reducing a bearish signal. Needham rating Zacks rating
• Positive Sentiment: Key clinical catalyst ahead: Vir plans to present topline Phase 3 ECLIPSE 1 results for elebsiran and tobevibart in chronic hepatitis delta at AASLD’s 2026 liver meeting. Positive data could be a meaningful catalyst, though the outcome is uncertain. AASLD data presentation
• Positive Sentiment: Cash runway extends into the second half of 2028, giving the company additional time to advance its pipeline and reach development milestones. Cash runway update
• Neutral Sentiment: Q3 loss beat expectations: Vir reported a loss of $0.57 per share, narrower than analysts’ expected loss of about $0.75–$0.80 and the $1.17 loss a year earlier. Q3 results
• Neutral Sentiment: An executive sold a small number of shares under a pre-arranged plan to cover tax withholding on vested equity awards; the stated purpose makes this less indicative of a change in outlook. SEC filing
• Negative Sentiment: Revenue missed sharply: Q3 revenue was negative $0.19 million versus analysts’ estimate of $0.98 million, and was down 178.3% year over year, tempering the earnings beat. Revenue results

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of Vir Biotechnology from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Friday, October 2nd. Raymond James Financial restated a “strong-buy” rating on shares of Vir Biotechnology in a report on Monday, September 28th. Needham & Company LLC increased their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Zacks Research raised shares of Vir Biotechnology from a “strong sell” rating to a “hold” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.14.

Vir Biotechnology Stock Performance

The firm has a fifty day simple moving average of $11.03 and a 200-day simple moving average of $9.61. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of -9.69 and a beta of 1.70.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.20. The firm had revenue of ($0.19) million for the quarter, compared to analyst estimates of $1.14 million. During the same period in the previous year, the business posted ($1.17) earnings per share. The business’s revenue for the quarter was down 178.3% on a year-over-year basis. Analysts expect that Vir Biotechnology, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Vir Biotechnology news, EVP Vanina de Verneuil sold 2,407 shares of Vir Biotechnology stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $11.10, for a total value of $26,717.70. Following the completion of the sale, the executive vice president owned 110,193 shares in the company, valued at $1,223,142.30. The trade was a 2.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in VIR. Fiduciary Financial Advisors acquired a new stake in shares of Vir Biotechnology in the second quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Vir Biotechnology in the third quarter valued at approximately $97,000. Caxton Associates LLP bought a new stake in shares of Vir Biotechnology in the first quarter valued at approximately $112,000. Amundi grew its position in Vir Biotechnology by 52.8% during the first quarter. Amundi now owns 15,315 shares of the company’s stock worth $137,000 after buying an additional 5,294 shares in the last quarter. Finally, Royal Bank of Canada grew its position in Vir Biotechnology by 223.1% during the first quarter. Royal Bank of Canada now owns 15,355 shares of the company’s stock worth $138,000 after buying an additional 10,603 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.